LQDA - Liquidia Corporation

Liquidia Corporation is a commercial-stage biopharmaceutical company focused on pulmonary arterial hypertension (PAH), with its primary product YUTREPIA (treprostinil inhalation powder) approved by the FDA in 2024 for treatment of PAH. The company sells YUTREPIA directly to specialty pharmacies and through specialty distributors serving PAH patients and prescribing physicians, operating on a direct pharmaceutical sales model with a small focused sales force. Revenue is in the early commercial ramp stage, sub-$50M annually, with operations and sales concentrated in the United States market. Liquidia also holds rights to LIQ861 pipeline assets and has been engaged in extended patent litigation with competitor United Therapeutics over treprostinil formulation patents.

Past Year Trends

• The Federal Circuit affirmed invalidity of United Therapeutics' key YUTREPIA-blocking patents in August 2024, ending a multi-year Hatch-Waxman injunction and enabling Liquidia to commercially launch YUTREPIA (treprostinil) inhalation powder in late 2024. (Bullish)
• Liquidia achieved its first-ever positive quarterly operating income of $1.767 million in Q3 2025 (ended September 30, 2025), compared to an operating loss of -$29.2 million in Q3 2024, reflecting YUTREPIA revenue ramp offsetting commercial launch costs. (Bullish)
• G&A expenses nearly doubled year-over-year to approximately $40 million in Q3 2025 versus $20 million in Q3 2024 as Liquidia built out a commercial salesforce and market access infrastructure to compete directly with United Therapeutics' Tyvaso DPI in the inhaled prostacyclin PAH market. (Bearish)

Next Year Trends

• YUTREPIA's formulary access and payer coverage decisions over the next 12 months will determine whether Liquidia can capture meaningful share of the approximately $3 billion inhaled prostacyclin PAH market dominated by United Therapeutics' Tyvaso DPI; pricing and step-edit restrictions by major PBMs represent the primary near-term revenue risk. (Bearish)
• Liquidia's pending FDA sNDA for YUTREPIA in pulmonary hypertension associated with interstitial lung disease (PH-ILD) represents a potential label expansion into a distinct patient population not currently served by Tyvaso DPI's approved indication, which could materially expand the addressable market if approved. (Bullish)
• With cash of approximately $157 million as of September 2025 and no traditional debt on the balance sheet, Liquidia must demonstrate YUTREPIA revenue growth sufficient to fund ongoing commercial operations without a dilutive equity raise, given continued net losses and rising current liabilities of $102.9 million. (Bearish)

Red Flags

No severe red flags identified as of August 2025.